查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947986

PNH治疗市场按治疗类型、作用机制、给药途径、最终用户和分销管道划分，全球预测，2026-2032年

Treatment of PNH Market by Treatment Type, Mechanism Of Action, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，阵发性夜间血红蛋白尿症 (PNH) 治疗市场价值将达到 15.7 亿美元，到 2026 年将增长至 16.4 亿美元，到 2032 年将达到 20.8 亿美元，复合年增长率为 4.08%。

关键市场统计数据
基准年 2025 15.7亿美元
预计年份：2026年 16.4亿美元
预测年份 2032 20.8亿美元
复合年增长率 (%) 4.08%

一个简洁的背景框架，阐述了影响当代阵发性睡眠性血红蛋白尿症（PNH）治疗决策的临床复杂性和不断变化的治疗重点。

阵发性睡眠性血尿症(PNH) 仍然是一种临床表现复杂的血液系统疾病，其特征是补体依赖性血管内溶血、骨髓衰竭风险以及血栓併发症，这些因素导致高发病率和治疗复杂性。过去十年，治疗进展已使 PNH 的治疗从以支持治疗为主转变为以标靶补体抑制剂治疗为主，从根本上改变了患者的病程和临床决策。本文整合了目前的临床范式，重点介绍了一类重新定义治疗目标的治疗药物，并提出了医疗保健相关人员现在必须回答的策略性问题，以优化治疗效果并维持医疗服务的可及性。

分子创新和基于真实世界证据的医学重塑如何共同重塑阵发性睡眠性血红蛋白尿症（PNH）的治疗方案、治疗模式和实证策略。

受分子创新、新型给药方式以及相关人员不断变化的期望驱动，阵发性睡眠性血红蛋白尿症 (PNH) 的治疗格局发生了变革性变化。长效 C5 抑制剂的出现降低了输注频率，并重塑了输液中心的利用模式；而近端补体途径抑制剂则引入了新的作用机制，带来了不同的疗效和安全性权衡。这些临床进展迫使临床医生和医疗系统重新评估治疗流程，将焦点从单纯的生化终点转向患者功能、血红蛋白稳定性以及输血独立性等综合指标。

关税趋势变化对生物製药供应链、筹资策略和医疗保健连续性基础设施的影响（至2025年）

到2025年，一系列政策变化和贸易趋势为生物製药生产、分销和临床应用领域的利益相关相关人员带来了新的财务和营运挑战。影响生物製药组件、一次性医疗设备和低温运输物流材料进口的关税调整，促使供应商重新检视其策略、库存缓衝和契约製造协议。因此，製造商和经销商正在重组其供应链，以降低关税波动带来的风险，加速区域采购，并实现契约製造合作伙伴的多元化，从而保障依赖先进生物疗法的患者的治疗连续性。

如何透过整合治疗类型、作用机制、给药途径、最终用户和分销管道等因素进行细分，从而驱动差异化的临床和营运策略

分段分析为评估阵发性睡眠性血红蛋白尿症 (PNH) 治疗的疗效、治疗途径和运作需求建立了框架。根据治疗类型，Eculizumab单抗、培塞他考普兰和Ravulizumab单抗之间的临床差异会影响到针对特异性机制的疗效、给药间隔和患者选择的决策，并且每种治疗方法都有其独特的监测和支持需求。根据作用机制，C3 抑制剂与 C5 抑制剂在溶血控制、感染风险以及潜在的联合或序贯给药策略方面具有重要意义。作用机制的选择决定了实验室监测的频率和预防性疫苗接种策略。

区域监管、报销和医疗服务趋势将对全球阵发性睡眠性血红蛋白尿症（PNH）治疗领域的治疗方案采纳和获取策略产生决定性影响。

区域趋势影响PNH治疗实施的关键，包括监管时间表、报销环境和医疗服务能力。在美洲，完善的法规结构和先进的专科医疗网络促进了新型治疗方法的快速应用，而支付方的谈判和医疗管理模式则对治疗使用模式和获取途径产生重大影响。尤其在美国，基于价值的合约和专科药房合作日益受到重视，这影响着患者接受输液和居家治疗的方式和地点。

药物研发者的策略重点与竞争动态影响PNH治疗产品的差异化、证据产生与取得途径。

大型生物製药公司之间的竞争以生命週期优化、产品组合差异化和策略联盟为特征。长期从事C5抑制剂研发的公司持续专注于製剂改进、延长给药间隔策略以及完善患者支持体系，以维持其临床相关性。同时，专注于近端补体抑制的新兴参与企业则基于特定的临床终点，宣称其产品具有显着的疗效和生活品质改善。每家公司都在进行不同的临床项目，包括头对头试验、治疗方案转换的疗效评估以及联合治疗，旨在为临床医生明确治疗顺序。

为业界领导者提供切实可行的临床、商业和供应链建议，以增强医疗服务可近性、累积实证医学证据并提供以患者为中心的医疗服务。

行业领导者应倡导临床、商业和营运方面的协作模式，以最大限度地改善患者疗效并确保患者可及性。首先，应优先制定实证策略，收集长期功能性疗效和医疗资源利用情况，以补充关键性试验结果。这些数据将有助于加强健保报销谈判，并支持差异化的价值提案。其次，应优化即时照护模式，尽可能投资于家庭给药的培训和基础设施建设，同时保持强大的输液中心能力，以满足需要静脉输液治疗的患者的需求。这种双管齐下的策略将减少系统瓶颈，并扩大患者的选择范围。

一种结合严谨的临床证据审查、专家访谈和检验的调查方法，旨在为实际研究结果提供支持。

调查方法结合了对同行评审文献、监管文件和临床试验註册库的系统性回顾，以及结构化的专家访谈和咨询，以建立强有力的证据基础。临床资料提取优先考虑随机对照试验、长期扩展研究和高品质观察性队列研究，以了解不同治疗层级的疗效、安全性和疗效持久性。研究人员审查了监管标籤和指导文件，以确定核准的适应症、给药方案和安全措施，同时检索了药物警戒资料库，以分析与补体抑制相关的信号检测和不利事件模式。

概述目前阵发性睡眠性血红蛋白尿症 (PNH) 治疗现状，整合临床创新、营运韧性和实证准入策略

这项综合分析表明，目前阵发性睡眠性血红蛋白尿症 (PNH) 的治疗环境日益多样化，操作也更加复杂，这主要受多种作用机制、替代给药途径以及不断变化的供应链因素的影响。治疗方案的选择不仅取决于溶血疗效，还取决于影响患者体验、现场可行性以及长期安全性监测的因素。不同地区的法规和报销制度差异，使得个人化的准入策略势在必行；而与关税相关的供应链压力，则进一步凸显了稳健的采购和生产方式的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法的PNH治疗市场

  • Eculizumab
  • 培塞他可普兰
  • Ravulizumab

9. 依作用机转分類的阵发性睡眠性血红素尿症（PNH）治疗市场

  • C3抑制剂
  • C5抑制剂

10. 按给药途径分類的 PNH 治疗市场

  • 静脉注射
  • 口服
  • 皮下注射

第十一章 按最终用户分類的 PNH 治疗市场

  • 居家医疗环境
  • 医院
  • 专科诊所

第十二章 按分销管道分類的 PNH 治疗市场

  • 网路药房
  • 线下药房

第十三章 按地区分類的PNH治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的 PNH 治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国阵发性睡眠性血红素尿症（PNH）治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 美国阵发性夜间血红素尿症（PNH）治疗市场

第十七章 中国阵发性睡眠性血红素尿症（PNH）治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Biocryst Pharmaceuticals Inc.
  • BioCryst Pharmaceuticals Inc.
  • Bristol Myers Squibb Company
  • Gilead Sciences Inc.
  • Ionis Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ra Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sobi Swedish Orphan Biovitrum AB
Product Code: MRR-4F7A6D4FB6C5

The Treatment of PNH Market was valued at USD 1.57 billion in 2025 and is projected to grow to USD 1.64 billion in 2026, with a CAGR of 4.08%, reaching USD 2.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.57 billion
Estimated Year [2026] USD 1.64 billion
Forecast Year [2032] USD 2.08 billion
CAGR (%) 4.08%

Concise contextual framing of clinical complexity and evolving therapeutic priorities that shape contemporary PNH treatment decision-making

Paroxysmal nocturnal hemoglobinuria remains a clinically complex hematologic disorder defined by complement-mediated intravascular hemolysis, bone marrow failure risk, and thrombotic complications that drive high morbidity and care complexity. Over the past decade therapeutic advances have shifted PNH from a supportive-care focus toward targeted complement inhibition, fundamentally changing patient trajectories and clinical decision-making. This introduction synthesizes the contemporary clinical paradigm, highlights the therapeutic classes that have redefined treatment goals, and frames the strategic questions healthcare stakeholders must now answer to optimize outcomes and sustain access.

Clinicians increasingly balance efficacy in hemolysis control with durability of response, administration burden, and safety considerations such as infection risk and breakthrough hemolysis. Meanwhile, payers and providers must reconcile increasingly sophisticated therapeutic options with systems-level constraints including infusion capacity, home-care viability, and specialty pharmacy networks. Patients are more informed and engaged than ever, prioritizing treatment convenience and quality-of-life improvements in addition to biological efficacy. This introduction establishes the context for the following analysis by clarifying the clinical, commercial, and operational drivers that will determine how treatment paradigms continue to evolve.

How molecular innovation and real-world evidence-driven care redesign are jointly reshaping treatment selection, delivery models, and evidence strategies across PNH

The landscape for PNH treatment has experienced transformative shifts driven by molecular innovation, novel delivery formats, and evolving stakeholder expectations. The emergence of long-acting C5 inhibitors has reduced infusion frequency and reshaped infusion center utilization, while proximal complement blockade has introduced alternative mechanisms with distinct efficacy and safety trade-offs. These clinical advances have forced clinicians and health systems to re-evaluate treatment algorithms, shifting attention from purely biochemical endpoints to integrated measures of patient function, hemoglobin stability, and transfusion independence.

Concurrently, the commercial environment has adapted; specialty pharmacy models, home infusion services, and bundled care pathways are being redesigned to accommodate both frequent-dosing subcutaneous options and extended-interval intravenous therapies. Regulatory pathways and labeling updates have accelerated lifecycle management strategies, prompting manufacturers to prioritize formulation innovation and patient support offerings. In addition, the increasing role of real-world evidence to demonstrate value and inform reimbursement has catalyzed new approaches to evidence generation, including registries and pragmatic studies that capture long-term safety and functional outcomes. The net effect is a treatment ecosystem that is more patient-centered, more diverse in therapeutic choice, and more operationally complex than in prior eras.

Implications of evolving tariff dynamics on biologics supply chains, procurement strategies, and continuity of care infrastructure through 2025

Policy changes and trade dynamics introduced in the lead-up to 2025 have created a new set of financial and operational considerations for stakeholders involved in biologics manufacturing, distribution, and clinical delivery. Tariff-related adjustments affecting imports of biologic components, single-use medical devices, and cold-chain logistics materials have translated into reassessments of supplier strategies, inventory buffering, and contract manufacturing arrangements. As a result, manufacturers and distributors have reconfigured supply chains to reduce exposure to tariff volatility, accelerate regional sourcing, and diversify contract manufacturing partners to protect continuity of care for patients reliant on high-acuity biologic therapies.

Healthcare providers and payers have likewise faced secondary impacts, including altered procurement costs for infusion supplies and ancillary disposables, shifted budgetary allocations for specialty pharmacy inventory, and increased emphasis on home-care models that reduce reliance on centralized infusion capacity. In response, some organizations have accelerated investments in domestic manufacturing capabilities and cold-chain resilience, while others have pursued procurement consortia to stabilize pricing and supply commitments. Importantly, these strategic shifts have underscored the value of transparent supply agreements and early engagement with logistics partners, since maintaining uninterrupted access to complement inhibitors is critical for preventing clinical decompensation in patients with PNH.

How integrated segmentation across treatment type, mechanism, administration route, end-user, and distribution channel drives differentiated clinical and operational strategies

Segmentation creates the framework through which therapeutic value, access pathways, and operational needs are evaluated for PNH treatments. Based on treatment type, the clinical differentiation among Eculizumab, Pegcetacoplan, and Ravulizumab informs decisions around mechanism-specific efficacy, dosing cadence, and patient selection, with each therapy presenting distinct monitoring and support requirements. Based on mechanism of action, the contrast between C3 inhibitors and C5 inhibitors has important implications for hemolysis control, infection risk profiles, and potential combination or sequential strategies; mechanism choice shapes laboratory monitoring frequency and prophylactic vaccination strategies.

Based on route of administration, the distribution of intravenous, oral, and subcutaneous options dictates site-of-care considerations, homecare feasibility, and specialty pharmacy engagement; intravenous therapies require infusion infrastructure, whereas subcutaneous formulations can expand home-based care and improve patient convenience. Based on end user, the needs of home care settings are different from hospitals and specialty clinics in terms of training, cold-chain management, and emergency backup plans, which in turn influence payer contracting and reimbursement coding. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each introduce unique inventory management, prior authorization workflows, and patient adherence support models that must be coordinated to ensure seamless treatment initiation and ongoing access.

Understanding these segmentation layers together enables stakeholders to align clinical pathways with operational capabilities, design appropriate patient support services, and prioritize investments in supply chain and distribution models that best match their patient populations and delivery contexts.

Regional regulatory, reimbursement, and care delivery dynamics that critically influence therapeutic adoption and access strategies across global PNH landscapes

Regional dynamics shape regulatory timelines, reimbursement environments, and care delivery capacities that are central to PNH treatment implementation. In the Americas, established regulatory frameworks and advanced specialty care networks facilitate rapid adoption of novel therapies, while payer negotiations and managed care mechanisms strongly influence utilization patterns and access pathways. The United States in particular has seen increased attention to value-based contracting and specialty pharmacy integration, which affects where and how patients receive infusions or home-administered therapies.

In Europe, Middle East & Africa, heterogeneity in national health systems and reimbursement approaches creates variable access landscapes that require localized market access strategies, including early engagement with health technology assessment bodies and tailored real-world evidence generation. Providers in these regions often balance centralized hospital-based infusion services with growing capabilities for homecare and outpatient delivery. In Asia-Pacific, the expansion of specialty care capacity, investments in domestic biomanufacturing, and evolving regulatory harmonization are enabling improved availability of advanced therapies, even as payer coverage and affordability remain key determinants of uptake. Across all regions, local clinical practices, vaccination protocols, and infection surveillance norms intersect with therapeutic selection and monitoring approaches, necessitating region-specific implementation plans and evidence packages.

Strategic priorities and competitive maneuvers among developers that shape product differentiation, evidence generation, and access pathways for PNH therapies

Competitive dynamics among leading biopharmaceutical organizations have been characterized by lifecycle optimization, portfolio differentiation, and strategic partnerships. The established sponsors of long-standing C5 inhibitors continue to focus on formulation improvements, extended-interval dosing strategies, and patient support frameworks to sustain clinical relevance, while newer entrants specializing in proximal complement blockade emphasize distinct efficacy and quality-of-life claims backed by targeted clinical endpoints. Companies are advancing a mix of clinical programs that evaluate head-to-head performance, switching outcomes, and combination approaches to clarify therapeutic sequencing for clinicians.

Commercial strategies reveal a dual focus on enhancing patient convenience through alternative routes of administration and on demonstrating downstream economic benefits through reduced transfusion needs, fewer thrombotic events, and lower acute-care utilization. Partnerships with specialty pharmacy providers and home infusion services are being used to expand access and streamline logistics. In parallel, some companies are investing in real-world evidence platforms and patient registries to document long-term outcomes and safety, thereby strengthening reimbursement dossiers and payer confidence. Intellectual property management, manufacturing scale-up, and strategic pricing agreements remain central themes as organizations seek to balance innovation incentives with broad patient access.

Practical clinical, commercial, and supply chain recommendations that industry leaders can implement to strengthen access, evidence generation, and patient-centric delivery

Industry leaders should pursue coordinated clinical, commercial, and operational actions to maximize patient outcomes and safeguard access. First, prioritize evidence-generation strategies that capture longitudinal functional outcomes and health resource utilization to complement pivotal trial results. These data will strengthen reimbursement discussions and support differentiated value propositions. Next, optimize site-of-care models by investing in training and infrastructure for home administration where feasible while maintaining robust infusion-center capabilities for patients requiring intravenous therapy; this dual approach reduces system bottlenecks and enhances patient choice.

Additionally, de-risk supply chains by diversifying suppliers, expanding regional manufacturing partnerships, and implementing inventory contingency plans to maintain continuity of biologic supply. Engage early and constructively with payers to design contracting arrangements that align incentives around clinical outcomes, including potential performance-based elements tied to transfusion independence or reduction in thrombotic events. Finally, deepen patient support services-education, adherence programs, and financial navigation-to reduce barriers to initiation and persistence, and integrate real-world evidence collection into these touchpoints to continuously validate long-term benefit and safety in heterogeneous patient populations.

Methodological approach combining rigorous clinical evidence review with expert interviews and triangulated validation to underpin actionable insights

The research methodology combined systematic review of peer-reviewed literature, regulatory documentation, and clinical trial registries with structured expert interviews and advisory consultations to produce a robust evidence base. Clinical data extraction prioritized randomized trials, long-term extension studies, and high-quality observational cohorts to capture efficacy, safety, and durability of response across therapeutic classes. Regulatory labeling and guidance documents were reviewed to map authorized indications, dosing regimens, and safety mitigations, while pharmacovigilance databases were examined for signal detection and adverse-event patterns relevant to complement inhibition.

Primary research included interviews with hematologists, specialty pharmacists, payer representatives, and home-care providers to validate operational assumptions and identify emerging practice patterns. Data triangulation techniques were applied to reconcile discrepancies between published evidence, expert opinion, and administrative workflows. All findings underwent quality assurance reviews, including cross-validation by clinical authors and methodological auditors, to ensure internal consistency and the highest standards of analytical rigor. Where applicable, sensitivity checks were performed on operational parameters and supply-chain scenarios to test the robustness of strategic implications derived from the evidence.

Synthesis of clinical innovation, operational resilience, and evidence-driven access strategies that summarize the contemporary state of PNH treatment

The collective analysis highlights a therapy landscape for PNH that is more diverse and operationally nuanced than ever, driven by differentiated mechanisms of action, alternative administration routes, and evolving supply-chain considerations. Treatment selection is now informed not only by hemolytic control but by factors affecting patient experience, site-of-care feasibility, and long-term safety monitoring. Regional differences in regulatory and reimbursement frameworks require tailored access strategies, and tariff-related supply-chain pressures have reinforced the need for resilient procurement and manufacturing approaches.

For stakeholders across clinical development, commercial operations, and healthcare delivery, the imperative is clear: integrate robust evidence generation with pragmatic logistics planning and patient-centric support models. Doing so will enable better-aligned therapeutic choices, smoother transitions between care settings, and sustained access. The outlook for PNH management is one of continued clinical innovation coupled with increasing emphasis on multidisciplinary systems that translate biological efficacy into durable, real-world patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treatment of PNH Market, by Treatment Type

  • 8.1. Eculizumab
  • 8.2. Pegcetacoplan
  • 8.3. Ravulizumab

9. Treatment of PNH Market, by Mechanism Of Action

  • 9.1. C3 Inhibitor
  • 9.2. C5 Inhibitor

10. Treatment of PNH Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Treatment of PNH Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Treatment of PNH Market, by Distribution Channel

  • 12.1. Online Pharmacy
  • 12.2. Offline Pharmacy

13. Treatment of PNH Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Treatment of PNH Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Treatment of PNH Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Treatment of PNH Market

17. China Treatment of PNH Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals Inc.
  • 18.7. Alnylam Pharmaceuticals Inc.
  • 18.8. Amgen Inc.
  • 18.9. Apellis Pharmaceuticals Inc.
  • 18.10. Astellas Pharma Inc.
  • 18.11. Biocryst Pharmaceuticals Inc.
  • 18.12. BioCryst Pharmaceuticals Inc.
  • 18.13. Bristol Myers Squibb Company
  • 18.14. Gilead Sciences Inc.
  • 18.15. Ionis Pharmaceuticals Inc.
  • 18.16. Johnson & Johnson
  • 18.17. Merck & Co. Inc.
  • 18.18. Novartis AG
  • 18.19. Pfizer Inc.
  • 18.20. Ra Pharmaceuticals Inc.
  • 18.21. Regeneron Pharmaceuticals Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi S.A.
  • 18.24. Sobi Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TREATMENT OF PNH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TREATMENT OF PNH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TREATMENT OF PNH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TREATMENT OF PNH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TREATMENT OF PNH MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TREATMENT OF PNH MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TREATMENT OF PNH MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TREATMENT OF PNH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS TREATMENT OF PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TREATMENT OF PNH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. NATO TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)